- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02461758
Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract which includes Crohn's disease (CD) and ulcerative colitis (UC). A recent epidemiological investigation estimates that nearly 4 million people worldwide are affected and approximately 1.4 million of these cases occur in the United States. IBD can lead to debilitating symptoms, hospitalizations, decreased quality of life, frequent procedures and/or surgery. Treatment options consist of immunosuppressive therapy, such as systemic corticosteroids, immunomodulators (thiopurines and methotrexate) and/or biologics, such as tumor necrosis factor alpha (TNF) agents or an integrin inhibitor, vedolizumab. They can achieve clinical remission and decrease the risk of complications, but also increase the risk for opportunistic infections, including influenza.
Multiple studies have shown lower influenza vaccine responses in patients with IBD compared to healthy individuals; IBD patients treated with TNF agents or combination therapy (TNF inhibitors and immunomodulators) are very likely to mount a poor immune response. Influenza serum antibody concentration correlates with protection from infection following vaccination. Therefore, increasing influenza antibody responses in patients with IBD would appear to be critical to improving protection from influenza. A high dose (HD) influenza vaccine containing four times more hemagglutinin was licensed based on its ability to induce higher antibody concentrations compared to standard dose (SD) in adults 65 years or older.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Hospital & Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
CASES Specific Aim #1 Inclusion Criteria
- A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic and histopathologic criteria.
- Ages 18-64
- Currently taking anti-TNF therapy (infliximab, golilumab, adalimumab, or certolizumab) for at least 3 months
- Exclusion Criteria
- Received season's influenza vaccine
- Allergy to eggs or influenza vaccine
- Currently use of systemic steroids in the past 3 months
Specific Aim #2 Inclusion criteria
- A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic and histopathologic criteria.
- Ages 18-64
- Currently on vedolizumab therapy
Exclusion Criteria
- Received season's influenza vaccine
- Allergy to eggs or influenza vaccine
- Currently use of systemic steroids in the past 3 months
Control group Inclusion criteria
- Age 18-64
- Willing to participate in study
Control group Exclusion criteria
- Currently on immunosuppressive therapy
- Has a chronic health condition that may have an impact on vaccine antibody concentrations as deemed by the investigators, including chronic liver disease, celiac disease, history of solid organ or bone marrow transplantation.
- Older than age 65 years
- Unconfirmed Measles, Mumps, and Rubella (MMR) vaccination status
- Patients in whom venipuncture are not feasible due to poor tolerability or lack of easy access.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Control Group
A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled.
All healthy individuals will receive standard dose influenza vaccine SDIV.
|
|
Other: Vedolizumab Group + standard dose influenza vaccine (SDIV)
A group of 20 patients who are currently on vedolizumab.
All individuals in this group will receive SDIV
|
|
Other: High dose influenza vaccine (HDIV)
This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy. 40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme. |
|
Other: Standard dose influenza vaccine (SDIV)
This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy. 40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine
Time Frame: Pre-immunization and 2-4 weeks post immunization
|
Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine. Higher antibody concentrations are associated with better protection from infection. |
Pre-immunization and 2-4 weeks post immunization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate Against Influenza Vaccine in Patients With Inflammatory Bowel Disease: Number of Participants Positive for Seroconversion
Time Frame: 4 weeks
|
Vaccine response rates for influenza vaccines in patients with inflammatory bowel disease will be accessed by number of patients who has shown significant seroconversion.
Seroconversion is defined as a four fold increase in antibody concentration from preimmunization to 4 weeks post immunization.
|
4 weeks
|
Seroprotection: Number of Participants With Antibody Concentration at Least 1:40 at Week 4 Postimmunization
Time Frame: 4 weeks
|
Seroprotection is defined as an antibody concentration of at least 1:40 at 4 weeks post-immunization which confers protection from infection in about 50% of individuals
|
4 weeks
|
Seroprotection: Number of Participants With Antibody Titer of 160 at Week 4 Post-immunization
Time Frame: 4 weeks
|
Seroprotection is defined by the FDA as post-immunization concentration of 1:160 that confers protection from infection to 95% of the population.
|
4 weeks
|
Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine
Time Frame: 6 months post-immunization
|
Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine. Higher antibody concentrations are associated with better protection from infection. |
6 months post-immunization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Freddy Caldera, University of Wisconsin School of Medicine and Public Health, Madison
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-0813
- Influenza in IBD (Other Identifier: Study Team)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease (IBD)
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Children's Mercy Hospital Kansas CityMedtronic - MITGCompleted
-
Zhongshan Hospital Xiamen UniversityCompletedInflammatory Bowel Disease(IBD)China
-
University College, LondonUnknownInflammatory Bowel Disease (IBD)
-
4SC AGCompletedInflammatory Bowel Disease (IBD)Germany, Bulgaria, Romania
Clinical Trials on Standard dose Influenza vaccine (SDIV)
-
Marshfield Clinic Research FoundationCenters for Disease Control and PreventionCompleted
-
Hospital Israelita Albert EinsteinMinistry of Health, BrazilCompletedAcute Coronary SyndromeBrazil
-
Brigham and Women's HospitalPatient-Centered Outcomes Research Institute; National Heart, Lung, and Blood... and other collaboratorsCompletedMyocardial Infarction | Heart FailureUnited States, Canada, Puerto Rico
-
University of PittsburghSanofi Pasteur, a Sanofi CompanyCompleted
-
Sanofi Pasteur, a Sanofi CompanySuspended
-
Oriol ManuelUniversity of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaboratorsCompletedInfluenza | Organ TransplantationSwitzerland, Spain
-
Sanofi Pasteur, a Sanofi CompanyRecruitingInfluenza ImmunizationUnited States, Puerto Rico
-
Vanderbilt UniversityCompletedPediatric Patients With Acute Lymphoblastic LeukemiaUnited States
-
Vanderbilt UniversityUniversity of Pittsburgh; MCM Vaccines B.V.CompletedPediatric Solid Organ Transplant PatientsUnited States